NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Jaguar Health, Inc. (JAGX) Stock Analysis

Jaguar Health, Inc. (JAGX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

JAGX

$0.60

−$0.10 (−13.98%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JAGX with… →

JAGX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.68
Previous Close
$0.69
Day's Range
0.57–0.68
52-Week Range
0.58–85.40
Volume
2.71M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.06
Valuation
Market Cap
$3.08M
P/E Ratio
0.01
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.11
EPS (ttm)Profit attributable to each share over the last twelve months.
98.20
Financials (FY)
Revenue (FY)
$11.51M−1.52%
Net Income (FY)
−$53.43M
Profit marginThe share of revenue left as profit after all costs and taxes.
−130.85%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.17M
1-Year Return
−63.82%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
124.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

JAGX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−35.88%
2025−95.98%

As of September 4, 2026.

JAGX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$11.51M−$53.43M−464.2%
2024$11.69M−$38.49M−329.3%
2023$9.76M−$41.30M−423.1%
2022$11.96M−$47.45M−396.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$11.51M$7.74M−$45.11M−$53.43M−464.2%
2024$11.69M$9.73M−$30.83M−$38.49M−329.3%
2023$9.76M$7.72M−$33.92M−$41.30M−423.1%
2022$11.96M$9.94M−$34.42M−$47.45M−396.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

JAGX Valuation vs Biotechnology Median

Median of 656 stocks
MetricJAGXBiotechnology medianvs median
P/E0.0112.570.0x the median
P/S ratio0.1115.260.0x the median
Profit margin−130.85%0.00%130.8 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Jaguar Health, Inc. (JAGX) is capitalised at $3.08M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 47 employees.

Over the past 52 weeks the price has ranged from $0.58 to $85.40. JAGX last closed at $0.60 on September 4, 2026. That is −$0.10 (−13.98%) against the previous close. The latest close sits 3.25% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $11.51M. Against the prior fiscal year total of $11.69M, that is a change of −1.52%. The same year closed with a net loss of $53.43M. Profit margin runs at −130.85%. That is 130.9 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to 98.2.

Across the 4 fiscal years on file, revenue moves from $11.96M in 2022 to $11.51M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

JAGX trades at a trailing price-to-earnings ratio of 0.01. That is 0 times the Biotechnology median of 12.57. The price-to-sales ratio is 0.11. On price-to-sales that is 0 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −63.82%. The stored price history starts on January 13, 2025, and the total return since then is −97.42%. Beta against the wider market is reported at −0.06. Daily returns over the trailing 1 year annualize to a volatility of 3,136.65%.

Growth & Income

The record shows no dividend for JAGX.

2026 is still running; the price is −35.88% year to date. The record holds one complete calendar year, 2025, which returned −95.98%.

Peer Comparison

Jaguar Health, Inc. (JAGX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Jaguar Health, Inc. JAGX $3.08M 0.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Jaguar Health, Inc. trades at a P/E of 0.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Jaguar Health, Inc.

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Visit website →